search
Back to results

EFS of the DUO System for Tricuspid Regurgitation (TANDEM II) (TANDEM II)

Primary Purpose

Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
DUO Transcatheter Tricuspid Coaptation Valve System
Sponsored by
CroiValve Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tricuspid Regurgitation focused on measuring Transcatheter, Coaptation Valve, TR, SVC, Tricuspid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Presence of severe or greater tricuspid regurgitation as determined by the Echo Core Lab. Patient is symptomatic despite medical therapy. The local Site Heart Team determines the Patient is appropriate for transcatheter valve intervention. The Patient's anatomy is suitable in the judgment of the Patient Selection Committee. Age ≥18 years The Patient has been informed of the nature of the study and agrees to its provisions and has provided written Informed Consent. Exclusion Criteria: Patient is currently participating in another clinical investigation that could affect the outcome of this trial. Any previous tricuspid valve intervention that would interfere with the placement of the investigational device. Moderate or greater tricuspid valve stenosis. Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation Pacemaker or implantable cardioverter-defibrillator (ICD) leads that would prevent appropriate placement of the investigational device. Need for concomitant surgical or interventional procedure, known at the time of screening (e.g., CABG, Atrial Septal Defect (ASD) repair). Ejection Fraction (EF) <25% Echocardiographic evidence of unstable intracardiac mass, thrombus or vegetation Patient has Systolic Pulmonary Pressure (sPAP) >60 mm Hg Severe hemodynamic instability: cardiogenic shock or the need for inotropic support or Intra-Aortic Balloon Pump (IABP) or other percutaneous ventricular assist devices Severe respiratory instability with continuous use of home oxygen Severe right ventricular dysfunction Untreated clinically significant coronary or carotid artery disease requiring revascularization surgical or interventional PCI. Stroke or transient ischemic event within 90 days prior to the index procedure Acute myocardial infarction within 30 days before the index procedure Renal insufficiency (eGFR <25 ml/min) or currently on chronic dialysis Active endocarditis within 6 months of the index procedure Pulmonary embolism or deep vein thrombosis within the last 6 months Any surgical, interventional, or transcatheter procedure within 30 days prior to the index procedure Hypertrophic cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis Life expectancy <1 year Active infections requiring current antibiotic therapy Known severe liver disease Is on the waiting list for a transplant or has had a prior heart or lung transplant Known active peptic ulcer or active GI bleed Unable to take anticoagulant therapy Any known major coagulation abnormalities, thrombocytopenia, platelets < 50,000/ml or severe anemia Hb <8 g/dl Known patient is actively abusing drugs Any known sensitivities or allergies to contrast (that cannot be adequately premedicated) and/or the device materials, including nickel and titanium Patients who are pregnant or intend to become pregnant Any condition making it unlikely the Patient will be able to complete all protocol procedures (including compliance with optimal medical therapy and immobility that would prevent completion of 6MWT), follow-up visits, or impact the scientific soundness of the clinical investigation result

Sites / Locations

  • Northwestern University
  • Montefiore Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment

Arm Description

Treatment with the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System)

Outcomes

Primary Outcome Measures

Freedom from device or procedure related MAEs
Death Reintervention Disabling stroke Myocardial infarction Major access site and vascular complications Severe bleeding Renal failure requiring dialysis Major cardiac structural complications Pulmonary embolism

Secondary Outcome Measures

Full Information

First Posted
May 31, 2023
Last Updated
August 22, 2023
Sponsor
CroiValve Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05913908
Brief Title
EFS of the DUO System for Tricuspid Regurgitation (TANDEM II)
Acronym
TANDEM II
Official Title
Early Feasibility Study of the DUO Transcatheter Tricuspid Coaptation Valve System in Patients With Tricuspid Regurgitation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
September 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CroiValve Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
Detailed Description
Multi-center, prospective, non-randomized, investigational, and pre-market. Data collected in this clinical study will include safety and function of the investigational system as well as up to 5 year clinical outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Keywords
Transcatheter, Coaptation Valve, TR, SVC, Tricuspid

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Treatment with the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System)
Intervention Type
Device
Intervention Name(s)
DUO Transcatheter Tricuspid Coaptation Valve System
Other Intervention Name(s)
DUO System
Intervention Description
Reduction of tricuspid regurgitation through a transcatheter approach
Primary Outcome Measure Information:
Title
Freedom from device or procedure related MAEs
Description
Death Reintervention Disabling stroke Myocardial infarction Major access site and vascular complications Severe bleeding Renal failure requiring dialysis Major cardiac structural complications Pulmonary embolism
Time Frame
At 30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presence of severe or greater tricuspid regurgitation as determined by the Echo Core Lab. Patient is symptomatic despite medical therapy. The local Site Heart Team determines the Patient is appropriate for transcatheter valve intervention. The Patient's anatomy is suitable in the judgment of the Patient Selection Committee. Age ≥18 years The Patient has been informed of the nature of the study and agrees to its provisions and has provided written Informed Consent. Exclusion Criteria: Patient is currently participating in another clinical investigation that could affect the outcome of this trial. Any previous tricuspid valve intervention that would interfere with the placement of the investigational device. Moderate or greater tricuspid valve stenosis. Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation Pacemaker or implantable cardioverter-defibrillator (ICD) leads that would prevent appropriate placement of the investigational device. Need for concomitant surgical or interventional procedure, known at the time of screening (e.g., CABG, Atrial Septal Defect (ASD) repair). Ejection Fraction (EF) <25% Echocardiographic evidence of unstable intracardiac mass, thrombus or vegetation Patient has Systolic Pulmonary Pressure (sPAP) >60 mm Hg Severe hemodynamic instability: cardiogenic shock or the need for inotropic support or Intra-Aortic Balloon Pump (IABP) or other percutaneous ventricular assist devices Severe respiratory instability with continuous use of home oxygen Severe right ventricular dysfunction Untreated clinically significant coronary or carotid artery disease requiring revascularization surgical or interventional PCI. Stroke or transient ischemic event within 90 days prior to the index procedure Acute myocardial infarction within 30 days before the index procedure Renal insufficiency (eGFR <25 ml/min) or currently on chronic dialysis Active endocarditis within 6 months of the index procedure Pulmonary embolism or deep vein thrombosis within the last 6 months Any surgical, interventional, or transcatheter procedure within 30 days prior to the index procedure Hypertrophic cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis Life expectancy <1 year Active infections requiring current antibiotic therapy Known severe liver disease Is on the waiting list for a transplant or has had a prior heart or lung transplant Known active peptic ulcer or active GI bleed Unable to take anticoagulant therapy Any known major coagulation abnormalities, thrombocytopenia, platelets < 50,000/ml or severe anemia Hb <8 g/dl Known patient is actively abusing drugs Any known sensitivities or allergies to contrast (that cannot be adequately premedicated) and/or the device materials, including nickel and titanium Patients who are pregnant or intend to become pregnant Any condition making it unlikely the Patient will be able to complete all protocol procedures (including compliance with optimal medical therapy and immobility that would prevent completion of 6MWT), follow-up visits, or impact the scientific soundness of the clinical investigation result
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Helen Scotch
Phone
+1-612-229-9950
Email
Helen@CroiValve.com
First Name & Middle Initial & Last Name or Official Title & Degree
Aubrey Dyer
Phone
+1-916-768-9141
Email
Aubrey@CroiValve.com
Facility Information:
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Huskin
Email
Anna.huskin@nm.org
First Name & Middle Initial & Last Name & Degree
Charles Davidson, MD
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kara Booth
Email
kbooth@montefiore.org
First Name & Middle Initial & Last Name & Degree
Azeem Latib, MD

12. IPD Sharing Statement

Learn more about this trial

EFS of the DUO System for Tricuspid Regurgitation (TANDEM II)

We'll reach out to this number within 24 hrs